Schedule 13G ownership disclosure

Halozyme Therapeutics Inc

Common Stock · CUSIP: 40637H109

Event date: 2025-06-30

Filing-level shares
12,612,300
Percent of class
10.2%
  • BlackRock, Inc.

    Shares: 12,612,300 · Class: 10.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0002052113-25-003063
Form type
SCHEDULE 13G/A
Filer
BlackRock, Inc.
CIK
CIK 2012383
Filed
Jul 17, 2025
Reporting period
Jun 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub